hello,大家下午好��！最近北方總是寒風陣陣，一瞅日歷，11月了！心情也隨之激動起來了有木有？咳咳，小編在此溫馨提示大家，挑仔細點！誓要成為最美買家秀知道不！   

不過嘛，言歸正傳，今天的產(chǎn)品小鼠不過節(jié)（B-NDG已經(jīng)在促銷了，再打折小編真要吃土了啊~），不多說，自產(chǎn)雙人源化B-hPD-1/hBTLA小鼠獻給大家~   

BTLA基因功能

    B細胞和T細胞衰減蛋白（B and T lymphocyte associated，BTLA）是另一種Ig超家族的檢查點負調(diào)分子，在結構上和CTLA4及PD-1類似，不僅表達于B細胞、T細胞、NK細胞，在樹突狀細胞和巨噬細胞中也有表達。BTLA與其配體HVEM（腫瘤壞死因子受體超家族成員）結合傳遞共抑制信號，在機體抗腫瘤免疫應答中發(fā)揮負性調(diào)節(jié)作用，并與腫瘤的免疫逃逸機制相關。 BTLA抑制劑可以增強TCR信號通路，并恢復T細胞功能，成為腫瘤生物治療潛在的新靶點。

Fig.1. (A) Interactions around PD1 and HVEM. PD1 belongs to the B7/CD28 (Immunoglobulin) superfamily and delivers negative signals upon binding to its ligands, PD-L1 and PD-L2. Recently, an unexpected interaction has been shown between PDL1 and CD80, whereby CD80 expressed on T cells can potentially behave as a receptor by delivering inhibitory signals when engaged by PDL1. CD80 and CD86 bind to the same two receptors, the stimulatory CD28 and the inhibitory CTL-associated-antigen-4 (CTLA-4) molecules. HVEM from the TNF/TNFR superfamily is clearly now a central immune molecule given the complexity of its interactions. HVEM has initially been discovered as the coreceptor for the glycoprotein D (gD) of the herpes simplex virus 1 (HSV-1), allowing the entry of the virus in the cell. HVEM interacts with LIGHT and lymphotoxin 3 to stimulate T cell responses. More recently, two novel ligands inhibiting T cell responses have been identified for HVEM: BTLA and CD160, a glycosphingolipid-linked protein, both belonging to the Ig superfamily, highlighting a crosstalk between the TNF-TNFR superfamily and the Ig superfamily. (B) Targeting coinhibitory molecules with monoclonal antibodies. Monoclonal antibodies (mAbs) are the primary immunotherapeutic modality used to promote immune function via antagonism or agonism of inhibitory or stimulatory molecular pathways, respectively. Cancer cells exploit the upregulation of coinhibitory molecules to inhibit T cell activation and to evade antitumor immunity. Indeed, PD1 is upregulated in TILs from many tumors and its ligands PDL1 and PDL2 are overexpressed in cancer cells. The anti-PD1 and anti-PDL1 mAbs block the interaction of PD1 with PDL1, reversing the inhibitory signaling and promoting lymphocyte activation. Similarly, high expression of BTLA was reported in tumor antigen-specific T cells from melanoma, thus BTLA would mediate inhibition of lymphocyte activation through engagement with its ligand HVEM expressed on tumors^[1].

hBTLA人源化小鼠

基本信息

打靶策略

B-hBTLA蛋白表達分析

圖2. B-hBTLA人源化小鼠脾細胞活化及流式檢測

結果顯示：在C57BL/6小鼠的B細胞中可檢測到mBTLA⁺細胞。在B-hBTLA純合鼠的B細胞中，可檢測到hBTLA⁺細胞。

抗人BTLA抗體藥效驗證

圖3.利用B-hBTLA小鼠進行抗人BTLA抗體藥效驗證實驗

將改造過的小鼠結腸癌MC38細胞（人源化HVEM并去除小鼠HVEM）移植到B-hBTLA純合小鼠體內(nèi)建立皮下腫瘤模型，待腫瘤體積約150±50mm3時將動物入組至對照組和治療組(n=6)。

結果顯示：相同劑量下，不同抗人BTLA抗體展現(xiàn)對腫瘤的抑制效果不同；同一抗人BTLA抗體，不同劑量下也展現(xiàn)出不同抑瘤效果。A. 腫瘤平均體積±SEM，B. 小鼠平均體重±SEM。 結果證明： B-hBTLA小鼠是評估人BTLA抗體體內(nèi)藥效的有力工具。

百奧賽圖利用自主開發(fā)的B-hPD-1/hBTLA 雙人源化小鼠，為研究該靶點抗體藥物的體內(nèi)藥效驗證提供了有效的模型和有力的工具！

B-hPD-1/hBTLA 雙人源化小鼠

基本信息

打靶策略

B-hPD-1/hBTLA小鼠蛋白表達分析

圖4. B-hPD-1/hBTLA人源化小鼠脾細胞活化及流式檢測

結果顯示：在C57BL/6小鼠中可檢測到mPD-1⁺細胞。在B-hPD-1/hBTLA純合鼠中，可檢測到hPD-1+細胞。

圖5. B-hPD-1/hBTLA人源化小鼠脾細胞活化及流式檢測

結果顯示：在C57BL/6小鼠中可檢測到mBTLA⁺細胞。在B-hPD-1/hBTLA純合鼠中，可檢測到hBTLA⁺細胞。

   百奧賽圖盛產(chǎn)各類基因打靶小鼠，免疫檢查點小鼠.....有意者歡迎隨時咨詢訂購哦~

參考文獻

[1]Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity

掃碼關注百奧賽圖了解更多咨詢哦